Previous close | 6.11 |
Open | 6.11 |
Bid | 5.83 x 400 |
Ask | 5.89 x 200 |
Day's range | 5.65 - 6.16 |
52-week range | 4.05 - 9.29 |
Volume | |
Avg. volume | 161,829 |
Market cap | 160.683M |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.83 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
ClearPoint Neuro showcases a 41% revenue increase and strategic expansions in biologics and capital equipment sectors.
First Quarter Revenue Growth +41%; Record Revenue AchievedSOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights Reported quarterly revenue of $7.6 million, a 41% year-over-year increase;Increased biologics and drug delivery revenue
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held in Baltimore, MD from May 7-11. The following original research abstracts will be presented at the Poster Session: De-Risking Clinical Trials Le